Jérémie Mbo Amvene
University of Ngaoundéré
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jérémie Mbo Amvene.
Cancer biology and medicine | 2017
Armel Herve Nwabo Kamdje; Paul Takam Kamga; Richard Tagne Simo; Lorella Vecchio; Paul Faustin Seke Etet; Jean Marc Muller; Giulio Bassi; Erique Lukong; Raghuveera Kumar Goel; Jérémie Mbo Amvene; Mauro Krampera
Master developmental pathways, such as Notch, Wnt, and Hedgehog, are signaling systems that control proliferation, cell death, motility, migration, and stemness. These systems are not only commonly activated in many solid tumors, where they drive or contribute to cancer initiation, but also in primary and metastatic tumor development. The reactivation of developmental pathways in cancer stroma favors the development of cancer stem cells and allows their maintenance, indicating these signaling pathways as particularly attractive targets for efficient anticancer therapies, especially in advanced primary tumors and metastatic cancers. Metastasis is the worst feature of cancer development. This feature results from a cascade of events emerging from the hijacking of epithelial-mesenchymal transition, angiogenesis, migration, and invasion by transforming cells and is associated with poor survival, drug resistance, and tumor relapse. In the present review, we summarize and discuss experimental data suggesting pivotal roles for developmental pathways in cancer development and metastasis, considering the therapeutic potential. Emerging targeted antimetastatic therapies based on Notch, Wnt, and Hedgehog pathways are also discussed.
Research and Reports in Biology | 2013
Paul Faustin Seke Etet; Armel Herve Nwabo Kamdje; Jérémie Mbo Amvene; Yousef H. Aldebasi; Mohammed Farahna; Lorella Vecchio
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php Research and Reports in Biology 2013:4 23–32 Research and Reports in Biology Dovepress
Journal of Analytical Oncology | 2017
Armel Herve Nwabo Kamdje; Georges Kalgong; Paul Takam Kamga; Richard Simo Tagne; Jérémie Mbo Amvene; Charlette Nangue
Background : Cervical cancer is a major cause of women death worldwide. The reduction of the mortality and morbidity of this pathology depends on the early detection based on powerful suitable screening methods, that will lead to optimal treatment strategies. However in some rural region of developing countries, it is very difficult to get access to standard screening methods, alternative screening methods, cheaper and easy to handle are then useful. Objective : The aim of this work was to test the sensitivity and specificity of VIA (Visual inspection with acetic acid) and VILI (Visual inspection with lugol iodine) as a diagnostic test of cervical cancer compared to the Pap Smear, evaluating the feasibility in health formation in the North Cameroon region, of implementing epidemiological surveillance of cervical cancer based on early diagnosis using the VIA-VILI association Method : 309 women age 20 to 62 years were recruited in this study, 307 were included in the statistical analyzes. Each woman was screened for cervical cancer by a conventional Smear and visual inspection with acetic acid 5% and the lugol solution. Results : We found in our study a prevalence of precancerous lesions of cervix at 12.70%. The risks factors of cervical cancer identified are age, matrimonial status, age of first sexual intercourse and parity. The association of VIA and VILI showed a sensitivity, specificity, positive and negative predictive value respectively about 93.58%; 97.01%; 82.01%, 99.04%. Conclusion : Compared to PAP Smear, VIA or VILI could be used as an alternative screening methods for cervical cancer in developing countries, where it is difficult to access to more accurate test such as colposcopy and biopsy.
Journal of Analytical Oncology | 2017
Armel Herve Nwabo Kamdje; Georges Kalgong; Richard Simo Tagne; Jérémie Mbo Amvene; Charlette Nangue
Abstract: Background : Cervical cancer is a major cause of women death worldwide. The reduction of the mortality and morbidity of this pathology depends on the early detection based on powerful suitable screening methods, that will lead to optimal treatment strategies. However in some rural region of developing countries, it is very difficult to get access to standard screening methods, alternative screening methods, cheaper and easy to handle are then useful. Objective : The aim of this work was to test the sensitivity and specificity of VIA (Visual inspection with acetic acid) and VILI (Visual inspection with lugol iodine) as screening test of cervical cancer compared to the Pap Smear, evaluating the feasibility in health formation in the North Cameroon region, of implementing epidemiological surveillance of cervical cancer based on early diagnosis using the VIA-VILI association Method : 309 women age 20 to 62 years were recruited in this study, 307 were included in the statistical analyzes. Each woman was screened for cervical cancer by a conventional Smear and visual inspection with acetic acid 5% and the lugol solution. Results : We found in our study a prevalence of precancerous lesions of cervix at 12.70%. The risks factors of cervical cancer identified are age, matrimonial status, age of first sexual intercourse and parity. The association of VIA and VILI showed a sensitivity, specificity, positive and negative predictive value respectively about 93.58%; 97.01%; 82.01%, 99.04%. Conclusion : Compared to PAP Smear, VIA or VILI could be used as an alternative screening methods for cervical cancer in developing countries. However, histology test was recommended to use a « Gold Standard » to evaluate the test accuracy of VIA/VILI because it can be used to diagnose cancer, while PAP smear cannot.
Cancer biology and medicine | 2017
Armel Herve Nwabo Kamdje; Paul Takam Kamga; Richard Tagne Simo; Lorella Vecchio; Paul Faustin Seke Etet; Jean Marc Muller; Giulio Bassi; Erique Lukong; Raghuveera Kumar Goel; Jérémie Mbo Amvene; Mauro Krampera
Journal of Diseases and Medicinal Plants | 2015
Simeon Pierre Chegaing Fodouop; Richard Tagne Simo; Jérémie Mbo Amvene; Emmanuel Talla; Paul Faustin Seke Etet; Paul Takam; Armel Herve Nwabo Kamdje; Jean-Marc Muller
HEALTH SCIENCES AND DISEASES | 2014
D Ngaroua; Nm Neossi; Jérémie Mbo Amvene; A Chichom Mefire; Nj Eloundou
HEALTH SCIENCES AND DISEASES | 2014
Etienne Belinga; Jérémie Mbo Amvene; Chatour Hanen; Ali El Housseini; Michel Voulgaroupoulos; Gilles Dauptain; Alain Cordesse; Samuel Nko'o Amvene
HEALTH SCIENCES AND DISEASES | 2018
Tsougmo Ngoufack; Olivier Pancha Mbouemboue; Alvine Touko; Habibah S. Haman; Pelagie D. Amanissa; Jérémie Mbo Amvene; Marcel Tangyi Tamanji
HEALTH SCIENCES AND DISEASES | 2018
Jean Claude Mballa Amougou; Jérémie Mbo Amvene; Bonaventure Jemea; Eric Magny Tiam; Alain Menanga; P Kaze Folefack; Christian Ouankou Ngongang; Brian Mbuagbaw; David Tagny Zukam; Samuel Nko'o Amvene